Skip to content
Screener

Ligand Pharmaceuticals LGND Gross carrying value

Gross carrying value at other companies

Gentex logo
GentexGNTX
$38.4M
Sirius XM logo
Sirius XMSIRI
$8.61B0.0%
Globe Life logo
Globe LifeGL
15%-2.0pp
Globe Life logo
Globe LifeGL
19%0.0pp
Globe Life logo
Globe LifeGL
8%-1.0pp
Sirius XM logo
Sirius XMSIRI
$570M0.0%

Segments

By product

See full
Agenus Inc.$40.82M

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemJune 30, 2026 / Gross carrying value(1)June 30, 2026 / AllowanceJune 30, 2026 / Net carrying value (1)December 31, 2025 / Gross carrying value(1)December 31, 2025 / AllowanceDecember 31, 2025 / Net carrying value(1)
Tolerance Therapeutics (Tzield®)25,470(99)25,37125,257(98)25,159
Ohtuvayre inventors19,957(179)19,77816,921(151)16,770
Elutia (CorMatrix)6,062(837)5,2256,607(1,107)5,500
AT2204,442(109)4,3335,132(132)5,000
Primrose mRNA3,281(98)3,1833,281(98)3,183
Zerion2,640(79)2,561
Others5,729(212)5,5175,769(214)5,555
Total financial royalty assets, net$209,699$(2,489)$207,210$222,375$(2,706)$219,669

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's gross carrying value?
Ligand Pharmaceuticals (LGND) reported gross carrying value of $209.7M in Q2 2026.
How has Ligand Pharmaceuticals's gross carrying value changed year-over-year?
Ligand Pharmaceuticals's gross carrying value increased by 1.5% year-over-year, from $206.62M to $209.7M.
What is the long-term trend for Ligand Pharmaceuticals's gross carrying value?
Over 2 years (2023 to 2025), Ligand Pharmaceuticals's gross carrying value has grown at a 77.8% compound annual growth rate (CAGR), from $70.36M to $222.38M.
What does gross carrying value mean?
Gross carrying value as reported by Ligand Pharmaceuticals Inc..

Ask your AI about Ligand Pharmaceuticals's gross carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude